Frankfurt/Munich—Global law firm Dentons has advised TQ Therapeutics GmbH on its acquisition of Juno Therapeutics GmbH. Simultaneously, Juno Therapeutics Inc., a leading biopharma company and wholly owned subsidiary of Bristol Myers Squibb, became a shareholder in TQ Therapeutics GmbH.

TQ Therapeutics GmbH, based in Planegg near Munich, is a biotechnology company that aims to advance the field of cell therapies through innovative technologies. The development of its novel cell processing platform is intended to enable advanced and affordable therapies for previously untreatable diseases such as rare autoimmune diseases and cancer.

The strategic transaction underscores TQ Therapeutics' commitment to making cell and gene therapies widely accessible to address the medical needs of diverse patient populations. The acquisition provides TQ Therapeutics with enhanced access to intellectual property and licensing agreements to further advance the development of its platform for ultra-short extracorporeal cell and gene therapies.

A Dentons team, led by Thomas Strassner and Dr. Michael Singer, provided comprehensive advice to TQ Therapeutics throughout the transaction process, covering all corporate and tax law issues.

Advisors to TQ Therapeutics:

Dentons (Frankfurt/Munich):

Corporate/M&A: Thomas Strassner (Partner), Dr. Michael Singer (Counsel, both lead), Edi Baqaie (Associate, all Munich)

Tax: Dr. Pia Dorfmueller (Partner), Konstantin Ecker (Associate, both Frankfurt)

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com